Annual Secretarial Complaince Report for Year ended 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals Ltd has filed its Annual Secretarial Compliance Report for the financial year ended 31 March 2025 with BSE (Scrip Code: 524703). The report was issued by Practising Company Secretary CS Swapnil J Dixit and signed by Pratika Mhambray, the company's Company Secretary and Compliance Officer. It covers the company's compliance with SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations, the Companies Act 2013, SEBI Insider Trading and Takeover Regulations, FEMA, and other applicable laws. The Practising Company Secretary reported no adverse observations or qualifications, indicating the company met its regulatory compliance requirements for the year.
This is a routine regulatory filing with no negative observations, which is neutral to mildly positive for shareholders as it confirms the company is meeting its compliance obligations. No immediate impact on stock price is expected from this filing.